出品｜搜狐财经 作者｜柴鑫洋 编辑｜李文贤 4月28日，沪上阿姨启动港股招股。 据了解，沪上阿姨此次在港上市拟全球发售约241万股H股，每股95.57港元/股至113.12港元/股。预期5月6日定价，5月8日开始在港交所交易。代码为 2589。 据灼识咨询资料，按2023年的GMV计算，沪上阿姨是中国第五大茶饮品牌，市场份额为4.6%。排在公司前面的分别是蜜雪冰城（20.2%）、古茗 （9.1%）、茶百道（8.0%）、霸王茶姬（5.0%）。 中国食品产业分析师朱丹蓬表示，新中式奶茶的竞争已经进入了全方位、多维度的竞争周期。如今的茶饮市场，既有门店数量的规模化竞争，也有品牌效 应的竞争，更多的则是在供应链体系上的竞争。 拟全球发售241万股H股，5月8日在港交所交易 沪上阿姨4月28日早间公告，在港上市拟全球发售约241万股H股，每股95.57港元/股至113.12港元/股。预期5月6日定价，5月8日开始在港交所交易。代码 为2589。 4月23日，沪上阿姨通过港交所上市聆讯。 搜狐财经注意到，去年情人节当天，沪上阿姨第一次向港交所递交招股书，年底，沪上阿姨又再次向递表。 沪上阿姨在招股书中表示，IPO募集所得 ...

4月28日，泡泡玛特(09992.HK)股价盘中一度暴涨超13%，达到195港元的历史新高，市值突破2600亿港 元。这一资本市场的热烈反响，与该公司旗下核心IP"LABUBU"第三代产品全球发售引发的消费热潮密 切相关。 4月24日，泡泡玛特旗下人气IP"LABUBU"在全球发售第三代搪胶毛绒产品"前方高能"系列，引发了全 球抢购风潮。发售当晚，"抢LABUBU"等相关词条便迅速登顶微博热搜，国内线上一经开售秒速售罄， 美国芝加哥、美国洛杉矶、英国伦敦及日本原宿等地的海外线下门店外连夜排起长龙。受此影响，泡泡 玛特官方APP下载量激增。七麦数据显示，4月25日，泡泡玛特APP首次登顶美国App Store购物榜，并 一跃成为了App Store免费总榜的第四名。 LABUBU的走红，颠覆了传统潮玩"可爱治愈"的审美逻辑。这只由香港艺术家龙家升设计的精灵，凭借 尖锐耳朵、夸张獠牙和搞怪表情，精准击中了Z世代追求个性表达的情绪需求。2024年以来，韩国女团 BLACKPINK成员Lisa的随身佩戴、国际巨星蕾哈娜的机场街拍，让LABUBU在社交媒体上迅速传播， 积累了极高的人气，泰国文旅部门甚至授予其"文旅体验 ...

4月28日，财政部公布数据，截至2025年3月末，全国地方政府债务余额501650亿元。其中，一般债务 170225亿元，专项债务331425亿元；政府债券500046亿元，非政府债券形式存量政府债务1604亿元。 截至2025年3月末，地方政府债券剩余平均年限10.0年，其中一般债券5.9年，专项债券12.2年；平均利 率2.99%，其中一般债券3.08%，专项债券2.95%。 ...

Group 1 - Northbound capital recorded a net purchase of 20.3 billion HKD in the Hong Kong stock market on April 28, with the Shanghai-Hong Kong Stock Connect seeing a net purchase of 23.43 billion HKD and the Shenzhen-Hong Kong Stock Connect experiencing a net sale of 3.13 billion HKD [1] - The stocks with the highest net purchases included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and CanSino Biologics (09926) [1] - The stocks with the highest net sales were Alibaba-W (09988), Tencent (00700), and Xiaomi Group-W (01810) [1] Group 2 - CanSino Biologics (09926) received a net purchase of 7.79 billion HKD, with a report indicating positive results from its clinical trial for the dual-specific antibody AK112 in treating advanced squamous non-small cell lung cancer [5] - Meituan-W (03690) saw a net purchase of 5.56 billion HKD, with analysts noting that the company does not face risks of ADR delisting and has stable revenue sources [5] - China Shenhua (01088) had a net purchase of 5.17 billion HKD, with analysts highlighting its strong cash flow supporting high dividend payouts despite pressure from falling coal prices [6] Group 3 - The Tracker Fund of Hong Kong (02800) and Hang Seng China Enterprises (02828) received net purchases of 20.43 billion HKD and 12.5 billion HKD, respectively, indicating increased investor confidence [4] - Tencent (00700) and Alibaba-W (09988) faced net sales of 5.97 billion HKD and 14.24 billion HKD, respectively, amid concerns regarding the ongoing US-China trade tensions [6] - China Mobile (00941) received a net purchase of 1.13 billion HKD, while Xiaomi Group-W (01810) and SMIC (00981) experienced net sales of 2.56 billion HKD and 1.36 billion HKD, respectively [6]

中国经济网北京4月28日讯阳光保险(06963.HK)港股今日收盘报3.42港元，跌幅2.29%。 公告显示，最终发售价定为每股发售股份5.83港元(不包括1.0%经纪佣金、0.0027%证监会交易征费、 0.00015%会财局交易征费及0.005%香港联交所交易费)。按最终发售价计算，经扣除公司就全球发售应 付的承销佣金及其他估计开支后，公司收取的全球发售所得款项净额约为6,419.5百万港元。 阳光保险港股目前处于破发状态。 南方都市报在报道《阳光保险两年多市值蒸发200亿港元》中指出，截至4月25日收盘报3.50港元，相较 上市时的发行价5.83港元下跌40%，市值蒸发超200亿港元。股价的持续低迷也对公司员工持股计划构 成压力。2016年2月，阳光保险曾召开股东大会，向核心员工配发了4.4亿股内资股，认购价为4元人民 币/股，并规定上市后三年内不得出售，锁定期满后每年减持不超过25%。这意味着员工持有的股票要 到2025年12月9日才能卖出。然而，如今阳光保险股价早已跌破认购价，导致参与计划的3688名员工面 临亏损。 阳光保险2025年4月25日发布2024年年报显示，集团总保费收入1,283.8亿 ...

南向资金今日净买入20.3亿元。港股通（沪）方面，康方生物、盈富基金分别获净买入11.38亿港元、 10.29亿港元；阿里巴巴-W净卖出额居首，金额为8.84亿港元；港股通（深）方面，恒生中国企业、盈 富基金分别获净买入12.51亿港元、10.14亿港元；阿里巴巴-W净卖出额居首，金额为5.41亿港元。 ...

Core Viewpoint - Universal Healthcare Group Limited ("Universal Healthcare", 2666.HK) has officially released its 2024 Environmental, Social, and Governance (ESG) report, showcasing its commitment to ESG responsibilities and addressing key concerns of stakeholders [1] ESG Strategy and Governance - In 2024, the company renamed its strategic committee to the Strategic and ESG Committee, marking a significant step in integrating ESG into its corporate strategy [1] - The company aims to align its development with public service, employee growth, environmental sustainability, and stakeholder collaboration [1] Healthcare Service Quality - Universal Healthcare has made significant advancements in specialized medical services, adding one national key specialty, three provincial clinical key specialties, and nine municipal clinical key specialties in 2024 [3] - The company has received over 100 quality-related awards and has made substantial improvements in hospital infrastructure, adding over 3,000 beds and 270,000 square meters of new construction [3] Digital Transformation and Innovation - The company is advancing its smart hospital initiatives and integrating digital solutions into its operations, with over 40 hospitals online and serving 41 million patients [4] - Universal Healthcare has achieved a 30% reduction in resource input and over 30% in total cost savings through centralized cloud deployment of approximately 200 application systems [4] Green Development Initiatives - The company is committed to green development, with new projects like the Xidian Hospital's outpatient and inpatient complex achieving a 16.97% energy-saving rate and reducing CO2 emissions by approximately 281.7 tons annually [5] - Universal Healthcare has successfully secured overseas ESG loans, with its green credit scale nearing 10 billion yuan by the end of 2024 [5] Employee Welfare and Rights - The company emphasizes employee rights and development, with a workforce of 22,885, of which 71.4% are women, and all employees receiving training [6] - Universal Healthcare has implemented a talent strategy to strengthen its workforce and ensure high-quality development [6] Social Responsibility and Community Engagement - The company has engaged in 12 charitable projects in 2024, assisting 699 patients and receiving recognition for its contributions to community health [7] - Universal Healthcare has been recognized for its long-term commitment to social welfare, including support for healthcare in remote areas [7] Recognition and Future Goals - In 2024, Universal Healthcare was ranked 63rd in CCTV's "Pioneer 100 ESG Listed Companies in China" and achieved a significant increase in its S&P Global ESG score [7] - The company aims to leverage its "medical, industry, and finance" synergy to enhance its ESG practices and contribute to sustainable development in China [8]

"五一"假期临近，国内市场即将迎来旅游餐饮消费高峰。海底捞后台数据显示，假期期间的用餐预订单 量正在快速上升，截至4月28日，全国门店已接到假期首日预订超2.5万桌。层出不穷的新场景、新玩 法、新产品，为消费者的假期带来了更多惊喜。(36氪) ...

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Biotech Theme Index, which reflects the overall performance of listed companies in the biotech sector from mainland China and Hong Kong [1][3] - The CSI Hong Kong-Shanghai Biotech Theme Index has shown an increase of 0.82% over the past month, 12.93% over the past three months, and 12.21% year-to-date [1] - The index consists of 50 sample companies involved in biopharmaceuticals, pharmaceuticals, and biotech services, with a base date of December 28, 2018, set at 1000.0 points [1] Group 2 - The top ten weighted companies in the index include: Heng Rui Medicine (13.16%), BeiGene (10.43%), WuXi AppTec (8.41%), Mindray Medical (7.71%), WuXi Biologics (5.15%), Innovent Biologics (4.82%), CanSino Biologics (3.91%), Shanghai Pharmaceuticals (2.74%), China National Pharmaceutical Group (2.45%), and Shanghai RAAS Blood Products (1.83%) [1] - The market share of the index holdings is distributed as follows: Hong Kong Stock Exchange 41.72%, Shanghai Stock Exchange 35.62%, and Shenzhen Stock Exchange 22.66% [1] Group 3 - In terms of industry composition, biopharmaceuticals account for 43.26%, chemical drugs for 25.78%, pharmaceutical and biotech services for 21.39%, and medical devices for 9.57% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Special circumstances may lead to temporary adjustments to the index, including the removal of samples that are delisted or changes due to mergers, acquisitions, or other corporate actions [2]

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Devices shows a recent decline, but has experienced significant growth over the past three months and year-to-date [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Medical Devices reported a recent value of 1194.94 points [1]. - Over the past month, the index has decreased by 3.48%, while it has increased by 15.43% over the last three months and 12.63% year-to-date [1]. Group 2: Index Composition - The index is composed entirely of securities listed on the Hong Kong Stock Exchange, with a sample that includes various sectors classified under the China Securities Industry Classification Standard [2]. - The index's sample shows that medical consumables account for 79.10%, medical devices for 16.57%, and in vitro diagnostics for 4.34% [2]. Group 3: Index Adjustments - The index samples are adjusted biannually, specifically on the second Friday of June and December, with weight factors fixed until the next scheduled adjustment [2]. - In cases of special events affecting the index sample, such as delisting or mergers, adjustments will be made accordingly [2].